Please identify the type of investor you are

By choosing an option you are acknowledging that this information is accurate and correctly identifies you.

SGH Medical Technology Fund

To provide long-term capital growth by investing in a portfolio of medical technology companies where innovation plays a crucial role in improving global health and economic outcomes. This includes biotechnology, pharmaceuticals, medical devices & equipment, medical data, information technology (e-health) and robotics.

Monthly Fact Sheet
How to invest

 

At a Glance

APIR code ETL2825AU mFund code - Minimum investment $20,000 Management cost 1.33% Distributions per annum 1 Commencement date 24/06/2021 Asset class Equity Benchmark S&P/ASX 200 Health Care Accumulation Index
Investment objective To provide long-term capital growth by investing in a portfolio of medical technology companies where innovation plays a crucial role in improving global health and economic outcomes. This includes biotechnology, pharmaceuticals, medical devices & equipment, medical data, information technology (e-health), and robotics.
Please refer to the current PDS and reference guide for further details including any additional fees that may be applicable.

Investment strategy

The Investment Manager seeks to achieve long-term capital growth by focusing stock selection on:

  1. Share valuation
  2. Company management and industry structure
  3. Behavioural factors to determine investment-timing

It is intended that the investment portfolio will consist of 40 to 60 companies split between:
Mature Growth – companies that have established medical products, generate revenue and are profitable. Typically, the medical technology is hard to disrupt or replicate and has a leading market position, e.g. CSL Limited.

Developing Growth – companies that have disruptive intellectual property in the medical technology space. Typically, these companies are in late-stage clinical trials or have registered or approved medical products, growing market access, and early-stage revenue.

Seed – companies that are involved in drug discovery, clinical trials or disruptive medical technology, e.g., start-ups. Typically, these are fast-growing and highly innovative companies with exponential growth potential from successful medical product commercialisation.

Unlisted and pre-Initial Public Offering (IPO) companies – these companies will typically reside in the “Seed” and “Developing Growth” stage of their life-cycle as defined above.

Investment parameters

  • The Fund will invest predominantly in medical technology companies and securities listed on the Australian Securities Exchange (ASX).
  • No more than 30% of the portfolio to be invested in international companies
  • Unlisted companies & pre-IPO companies with maximum portfolio exposure of 20%
  • Minimum number of stocks 40 (no maximum limit)
  • Maximum cash holding of 20%
  • No more than 10% of the market value of the portfolio to be held in any company
  • No more than 10% of a company’s issued capital
  • The Fund is not permitted to be geared or deal in derivatives
  • The Fund can borrow up to 5% of NAV to meet redemption requests

Performance as at 31 August 2021. Powered by data from Financial Express. For funds with less than 5 yrs performance history, refer to fact sheet for since inception returns.

 

Performance
Performance 1M 3M 6M 1Y 3Y 5Y 7Y 10Y Entry Nav Exit Date History
MOREBACK
Fund Name 2.67% - - - - - - - $1.0197 $1.0161 $1.0125 16/09/2021

HOW TO INVEST

Existing SGH or DMP investor with Mainstream investor number:

  1. Download and read PDS and reference guide.
  2. Complete additional investment form and send to Mainstream Fund Services Unit Registry.

Please contact Mainstream Fund Services at 1300 133 451 if you require assistance.

Not an existing SGH or DMP investor:

  1. Download and read PDS and reference guide.
  2. Submit application form online.

OR

  1. Download and read PDS and reference guide.
  2. Complete an application form and send to Mainstream Fund Services Unit Registry.

RESEARCH RATINGS